Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Seoulin Bioscience Co Ltd banner
S

Seoulin Bioscience Co Ltd
KOSDAQ:038070

Watchlist Manager
Seoulin Bioscience Co Ltd
KOSDAQ:038070
Watchlist
Price: 4 055 KRW -1.82% Market Closed
Market Cap: ₩37.7B
Write Note Create Alert Ask AI

Wall St Price Targets

Price Targets Summary
Seoulin Bioscience Co Ltd

There are no price targets for Seoulin Bioscience Co Ltd.
Lowest Forecast
Wall Street Target
Not Available
Average Forecast
Wall Street Target
Not Available
Highest Forecast
Wall Street Target
Not Available
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Seoulin Bioscience Co Ltd Competitors:
Price Targets

Revenue
Forecast

5% / Year
Past Growth
-7% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
5% / Year
Past Growth
-7% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 12 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 11 years is -7%.

What are analyst estimates?

Gross Profit
Forecast

3% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
3% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Seoulin Bioscience Co Ltd

Operating Income
Forecast

-14% / Year
Past Growth
14% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
-14% / Year
Past Growth
14% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 12 years, the compound annual growth rate for Operating Income has been -14%. The projected CAGR for the next 11 years is 14%.

What are analyst estimates?

Pre-Tax Income
Forecast

-14% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
-14% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Seoulin Bioscience Co Ltd

Net Income
Forecast

-13% / Year
Past Growth
14% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
-13% / Year
Past Growth
14% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 12 years, the compound annual growth rate for Net Income has been -13%. The projected CAGR for the next 11 years is 14%.

What are analyst estimates?

Continue Research

Summary
intrinsic value, competitors valuation, and company profile.
DCF Valuation
stock valuation using Discount Cash Flow valuation method.
Relative Valuation
stock valuation using valuation multiples.
Wall St Estimates
price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is Seoulin Bioscience Co Ltd's stock price target?
Not Available

Seoulin Bioscience Co Ltd does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Seoulin Bioscience Co Ltd?
Projected CAGR
-7%

Over the last 12 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 11 years is -7%.

What is the Operating Income forecast for Seoulin Bioscience Co Ltd?
Projected CAGR
14%

Over the last 12 years, the compound annual growth rate for Operating Income has been -14%. The projected CAGR for the next 11 years is 14%.

What is the Net Income forecast for Seoulin Bioscience Co Ltd?
Projected CAGR
14%

Over the last 12 years, the compound annual growth rate for Net Income has been -13%. The projected CAGR for the next 11 years is 14%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett